3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Multiple Myeloma
307
Recurrence
64
Neoplasms
32
Neoplasms, Plasma Cell
17
Lymphoma, Non-Hodgkin
14
Carcinoma, Non-Small-Cell Lung
13
Prostatic Neoplasms
12
Vomiting
11
Neoplasm Metastasis
8
Leukemia, Myeloid, Acute
8
Precursor Cell Lymphoblastic Leukemia-Lymphoma
7
Nausea
7
Lymphoma, Large B-Cell, Diffuse
7
Lymphoma
7
Ovarian Neoplasms
6
Immunoglobulin Light-chain Amyloidosis
6
Hematologic Neoplasms
6
Parkinson Disease 4, Autosomal Dominant Lewy Body
5
Paraproteinemias
5
Lung Neoplasms
5
Leukemia
5
Small Cell Lung Carcinoma
4
Renal Insufficiency
4
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
4
Plasmacytoma
4
Lymphoma, Follicular
4
Hematologic Diseases
4
Leukemia, Plasma Cell
3
Leukemia, Lymphocytic, Chronic, B-Cell
3
Breast Neoplasms
3
Interventions
Paclitaxel
18
pembrolizumab
16
Cisplatin
16
Fluorouracil
15
Irinotecan
13
tislelizumab
9
Oxaliplatin
8
Nivolumab
8
Docetaxel
8
Leucovorin
6
Capecitabine
5
spartalizumab
4
Levoleucovorin
4
Carboplatin
4
lenvatinib
3
durvalumab
3
Radiotherapy
3
Drug Therapy
3
toripalimab
2
sintilimab
2
regorafenib
2
elgemtumab
2
atezolizumab
2
Itraconazole
2
Injections
2
Gemcitabine
2
Bevacizumab
2
130-nm albumin-bound paclitaxel
2
tremelimumab
1
sitravatinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Esophageal Squamous Cell Carcinoma
×
Dexamethasone
×
Clear all
NCT05319730
2026-05-26
MK-3475-06B
Merck Sharp & Dohme LLC
Phase 1/2
Recruiting
230 enrolled